• Something wrong with this record ?

Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience

D. Orbach, B. Brennan, A. De Paoli, S. Gallego, P. Mudry, N. Francotte, M. van Noesel, A. Kelsey, R. Alaggio, D. Ranchère, GL. De Salvo, M. Casanova, C. Bergeron, JH. Merks, M. Jenney, MC. Stevens, G. Bisogno, A. Ferrari,

. 2016 ; 57 (-) : 1-9. [pub] 20160202

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16027690

BACKGROUND: Infantile fibrosarcoma (IFS) is a very rare disease occurring in young infants characterised by a high local aggressiveness but overall with a favourable survival. To try to reduce the total burden of therapy, the European pediatric Soft tissue sarcoma Study Group has developed conservative therapeutic recommendations according to initial resectability. MATERIAL AND METHODS: Between 2005 and 2012, children with localised IFS were prospectively registered. Initial surgery was suggested only if possible without mutilation. Patients with initial complete (IRS-group I/R0) or microscopic incomplete (group II/R1) resection had no further therapy. Patients with initial inoperable tumour (group III/R2) received first-line vincristine-actinomycin-D chemotherapy (VA). Delayed conservative surgery was planned after tumour reduction. Aggressive local therapy (mutilating surgery or external radiotherapy) was discouraged. RESULTS: A total of 50 infants (median age 1.4 months), were included in the study. ETV6-NTRK3 transcript was present in 87.2% of patients where investigation was performed. According to initial surgery, 11 patients were classified as group I, 8 as group II and 31 as group III. VA chemotherapy was first delivered to 25 children with IRS-III/R2 and one with IRS-II/R1 disease. Response rate to VA was 68.0%. Mutilating surgery was only performed in three cases. After a median follow-up of 4.7 years (range 1.9-9.0), 3-year event-free survival and overall survival were respectively 84.0% (95% confidence interval [CI] 70.5-91.7) and 94.0% (95% CI 82.5-98.0). CONCLUSIONS: Conservative therapy is possible in IFS as only three children required mutilating surgery, and alkylating or anthracycline based chemotherapy was avoided in 71.0% of patients needing chemotherapy. VA regimen should be first line therapy in order to reduce long term effects.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027690
003      
CZ-PrNML
005      
20161021123201.0
007      
ta
008      
161005s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejca.2015.12.028 $2 doi
024    7_
$a 10.1016/j.ejca.2015.12.028 $2 doi
035    __
$a (PubMed)26849118
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Orbach, Daniel $u Department of Pediatric, Adolescent and Young Adult Oncology, Institut Curie, Paris, France. Electronic address: daniel.orbach@curie.fr.
245    10
$a Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience / $c D. Orbach, B. Brennan, A. De Paoli, S. Gallego, P. Mudry, N. Francotte, M. van Noesel, A. Kelsey, R. Alaggio, D. Ranchère, GL. De Salvo, M. Casanova, C. Bergeron, JH. Merks, M. Jenney, MC. Stevens, G. Bisogno, A. Ferrari,
520    9_
$a BACKGROUND: Infantile fibrosarcoma (IFS) is a very rare disease occurring in young infants characterised by a high local aggressiveness but overall with a favourable survival. To try to reduce the total burden of therapy, the European pediatric Soft tissue sarcoma Study Group has developed conservative therapeutic recommendations according to initial resectability. MATERIAL AND METHODS: Between 2005 and 2012, children with localised IFS were prospectively registered. Initial surgery was suggested only if possible without mutilation. Patients with initial complete (IRS-group I/R0) or microscopic incomplete (group II/R1) resection had no further therapy. Patients with initial inoperable tumour (group III/R2) received first-line vincristine-actinomycin-D chemotherapy (VA). Delayed conservative surgery was planned after tumour reduction. Aggressive local therapy (mutilating surgery or external radiotherapy) was discouraged. RESULTS: A total of 50 infants (median age 1.4 months), were included in the study. ETV6-NTRK3 transcript was present in 87.2% of patients where investigation was performed. According to initial surgery, 11 patients were classified as group I, 8 as group II and 31 as group III. VA chemotherapy was first delivered to 25 children with IRS-III/R2 and one with IRS-II/R1 disease. Response rate to VA was 68.0%. Mutilating surgery was only performed in three cases. After a median follow-up of 4.7 years (range 1.9-9.0), 3-year event-free survival and overall survival were respectively 84.0% (95% confidence interval [CI] 70.5-91.7) and 94.0% (95% CI 82.5-98.0). CONCLUSIONS: Conservative therapy is possible in IFS as only three children required mutilating surgery, and alkylating or anthracycline based chemotherapy was avoided in 71.0% of patients needing chemotherapy. VA regimen should be first line therapy in order to reduce long term effects.
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a adjuvantní chemoterapie $x metody $7 D017024
650    _2
$a kombinovaná terapie $x metody $7 D003131
650    _2
$a osobní újma zaviněná nemocí $7 D017281
650    _2
$a daktinomycin $x aplikace a dávkování $7 D003609
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a studie proveditelnosti $7 D005240
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibrosarkom $x farmakoterapie $x patologie $x chirurgie $7 D005354
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a staging nádorů $7 D009367
650    _2
$a prospektivní studie $7 D011446
650    _2
$a reoperace $7 D012086
650    _2
$a nádory měkkých tkání $x farmakoterapie $x patologie $x chirurgie $7 D012983
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vinkristin $x aplikace a dávkování $7 D014750
650    _2
$a pozorné vyčkávání $7 D057832
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Brennan, Bernadette $u Department of Pediatric Oncology, Royal Manchester Children's Hospital, Manchester, United Kingdom.
700    1_
$a De Paoli, Angela $u Clinical Trials and Biostatistics Unit, IRCCS Istituto Oncologico Veneto, Padova, Italy.
700    1_
$a Gallego, Soledad $u Paediatric Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
700    1_
$a Mudry, Peter $u Department of Pediatric Oncology, University Children's Hospital, Brno, Czech Republic.
700    1_
$a Francotte, Nadine $u Department of Pediatrics, CHC-Clinique Esperance, Montegnée, Belgium.
700    1_
$a van Noesel, Max $u Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
700    1_
$a Kelsey, Anna $u Department of Diagnostic Paediatric Histopathology, Royal Manchester Children's Hospital, Manchester, United Kingdom.
700    1_
$a Alaggio, Rita $u Pathology Department, Padova University, Padova, Italy. $7 gn_A_00003231
700    1_
$a Ranchère, Dominique $u Pathology Department, Institut d'Hematologie et d'Oncologie Pediatrique, Centre Léon Bérard, Lyon, France.
700    1_
$a De Salvo, Gian Luca $u Clinical Trials and Biostatistics Unit, IRCCS Istituto Oncologico Veneto, Padova, Italy.
700    1_
$a Casanova, Michela $u Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
700    1_
$a Bergeron, Christophe $u Department of Pediatric Oncology, Institut d'Hematologie et d'Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France.
700    1_
$a Merks, Johannes H M $u Department of Pediatric Oncology, Emma Children's Hospital-Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
700    1_
$a Jenney, Meriel $u Department of Pediatric Oncology, Children's Hospital for Wales, Heath Park, Cardiff, United Kingdom.
700    1_
$a Stevens, Michael C G $u Department of Pediatric Oncology, Royal Hospital for Children, University of Bristol, United Kingdom.
700    1_
$a Bisogno, Gianni $u Pediatric Hematology and Oncology Division, Padova University, Padova, Italy.
700    1_
$a Ferrari, Andrea $u Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
773    0_
$w MED00009626 $t European journal of cancer (Oxford, England 1990) $x 1879-0852 $g Roč. 57, č. - (2016), s. 1-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26849118 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161021123610 $b ABA008
999    __
$a ok $b bmc $g 1166004 $s 952320
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 57 $c - $d 1-9 $e 20160202 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Archiving options